Pfizer expands anti-infectives pipeline with acquisition

29 April 2021
pfizer_colour_new_large

US pharma giant Pfizer (NYSE: PFE) said yesterday that it has acquired San Diego-based Amplyx Pharmaceuticals, a privately-held biotech dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

Amplyx’ lead compound, fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. Financial terms of this acquisition were not disclosed.

In addition to fosmanogepix, Pfizer acquires Amplyx' early-stage pipeline, including potential antiviral (MAU868) and antifungal (APX2039) therapies. MAU868, licensed from Novartis (NOVN: VX), is a potent neutralizing monoclonal antibody with activity against the BK virus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology